Linked Life Data

19687350

Source:http://linkedlifedata.com/resource/pubmed/id/19687350

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-9-17
pubmed:abstractText
Left ventricular hypertrophy, a major cardiovascular risk factor for morbidity and mortality, is commonly caused by arterial hypertension. The renin-angiotensin-aldosterone system may contribute to the pathogenesis of left ventricular hypertrophy. The Assessment of Lotrel in Left Ventricular Hypertrophy and Hypertension Study compared a single-pill combination of amlodipine/benazepril at doses 5.0/20.0 mg, 5.0/40.0 mg, and 10.0/40.0 mg with hydrochlorothiazide/benazepril at doses 12.5/20.0 mg, 12.5/40.0 mg, and 25.0/40.0 mg on the reduction of left ventricular mass index measured by cardiac MRI in stage 2 hypertensive patients over 52 weeks of treatment in a randomized clinical trial. A total of 125 male and female patients, > or =55 years of age, with echocardiographic left ventricular hypertrophy and high-risk hypertension defined as blood pressure > or =160/100 mm Hg or current antihypertensive treatment were enrolled. After 52 weeks of treatment, left ventricular mass index was significantly reduced from baseline with amlodipine/benazepril (mean: 10.16 g/m(2)) or hydrochlorothiazide/benazepril (mean: 6.74 g/m(2); both P<0.0001), with a mean difference between treatment groups of 3.36 g/m(2) (P=0.16). No significant treatment differences were observed in subgroups defined by age, male gender, race, diabetes status, or dose level. However, in female patients, left ventricular mass index reduction was greater with amlodipine/benazepril (P=0.02). Both treatments were well tolerated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1524-4563
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
731-7
pubmed:meshHeading
pubmed-meshheading:19687350-Aged, pubmed-meshheading:19687350-Amlodipine, pubmed-meshheading:19687350-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:19687350-Benzazepines, pubmed-meshheading:19687350-Calcium Channel Blockers, pubmed-meshheading:19687350-Diuretics, pubmed-meshheading:19687350-Dose-Response Relationship, Drug, pubmed-meshheading:19687350-Double-Blind Method, pubmed-meshheading:19687350-Drug Combinations, pubmed-meshheading:19687350-Female, pubmed-meshheading:19687350-Heart Ventricles, pubmed-meshheading:19687350-Humans, pubmed-meshheading:19687350-Hydrochlorothiazide, pubmed-meshheading:19687350-Hypertension, pubmed-meshheading:19687350-Hypertrophy, Left Ventricular, pubmed-meshheading:19687350-Magnetic Resonance Imaging, pubmed-meshheading:19687350-Male, pubmed-meshheading:19687350-Middle Aged, pubmed-meshheading:19687350-Risk Factors, pubmed-meshheading:19687350-Sex Characteristics, pubmed-meshheading:19687350-Treatment Outcome
pubmed:year
2009
pubmed:articleTitle
Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension.
pubmed:affiliation
Research Department, St Francis Hospital, 100 Port Washington Blvd., Roslyn, NY 11576, USA. Nathaniel.Reichek@chsli.org
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study